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ECONOMIC EVALUATION OF DATSCAN IN THE DIAGNOSIS OF PARKINSONISM
2 Amersham Health, Bucks, NA, United Kingdom OBJECTIVES: Parkinsonian syndromes (PS) can be difficult to diagnose clinically, the most common condition misdiagnosed as PS being essential tremor (ET). DaTSCAN (123I-FP-CIT) SPECT imaging accurately differentiates PS with dopaminergic deficit from ET in patients with uncertain clinical diagnosis (sensitivity 95%, specificity 93%). This study aimed to assess the economic value of using DaTSCAN to the Belgian Health care system. METHODS: A Markov model was developed to simulate a cohort of patients with clinically uncertain PS managed over 5 years 1) without DaTSCAN (treatment based on clinical judgement), or 2) all patients receiving DaTSCAN at the outset. Health states were defined by type of therapy (PS first-line, PS second-line, ET, none) and underlying condition (PS, ET). The model estimated time on appropriate therapy (PS therapy for underlying PS, ET therapy for underlying ET) and patient management costs. Model inputs were from published studies, with treatment patterns/resource use from a Delphi panel of 13 Belgian physicians. 53% cohort members were assumed to have true PS. Costs were from official sources, the test cost (agent plus administration) being €900. RESULTS: Without DaTSCAN, 41% of cohort members were treated appropriately at the outset, rising to 75% at 5 years. Using DaTSCAN, 94% of patients were treated appropriately at the outset, declining to 77% at 5 years. DaTSCAN use generated an incremental 1.40 "adequately treated years" at a net cost of €140 per patient. This result was sensitive to the underlying prevalence of PS, but relatively robust to variations in other model parameters, such as rates of adverse events and withdrawal from therapy. CONCLUSION: Treatment of patients with clinically uncertain PS based on DatSCAN rather than clinical judgement may be considered to be an economically favourable strategy. An increase in time on appropriate therapy is achieved at modest extra cost to the Health care system. The management of a chronic disease must integrate the needs induced by the disease on the patient's surroundings. OBJECTIVE: The TRILOGIE study was initiated by a group of neurological and neuro-paediatric experts and the Ligue Francaise Contre l'Epilepsie to study the ChildParent-Epilepsy interaction. The objective is to assess the socio-economic consequences of epilepsy on the daily life of the parents of a child diagnosed as epileptic for more than six months. METHODS: Self-administered questionnaires, created on the basis of interviews with families of epileptic children, were sent to paediatricians and neuro-paediatricians taking care of epileptic children, as well as to members of patients' associations. They then distributed them to the parents of the children concerned.
PNM14
SOCIO-ECONOMIC IMPACT OF EPILEPSY ON PARENTS: THE TRILOGY STUDY
RESULTS:
The results concerned a population of 668 parents of epileptic children. Eight domains were explored as part of the study. The management of the disease is often difficult with more than one hospitalisation (70% of the children). The consequences for the children are serious difficulties at school (40%) and a greater need for care (63%). Medical and/or psychological help is therefore often needed by the parents (38%). Epilepsy is source of conflict for 43% of the couples. The major economic impact of the disease is due to partial reimbursement of nursing costs, extra costs of care and schooling and loss of revenue due to one parent giving up full time work. CONCLUSIONS: TRILOGIE underlines the parent's need for information concerning: the current and future treament of the disease, the possibilities of scolarisation and the concrete daily help.
